Cambium Bio secures $2.4M Iivestment from major shareholder ZYBT
Cambium Bio (ASX:CMB), a clinical-stage regenerative medicine company specialising in ophthalmology and tissue repair, has secured a $2.4 million strategic investment from its major shareholder, Zheng Yang Biomedical Technology.











